The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies

Wilkinson-Berka, Jennifer L.; Deliyanti, Devy

doi:10.21037/atm.2016.10.27

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vasotide ( D (Cys-Leu-Pro-Arg-Cys)) is a potent peptidomimetic that was designed for angiogenesis targeting. Vasotide is a VEGF receptor-targeted prototype peptidomimetic that binds effectively to NRP-1 and VEGFR-1 (Wilkinson-Berka and Deliyanti 2016 ). Richard et al (Sidman et al 2015 ) have shown that the Vasotide can reduce pathological angiogenesis in two preclinical murine models and one nonhuman primate model of human retinal diseases.…”

Section: The Ability Of Peptidomimetics On Angiogenesis Inhibitionmentioning

confidence: 99%

Peptidomimetics in cancer targeting

Gomari

Abkhiz

Pour

et al. 2022

Mol Med

View full text Add to dashboard Cite

The low efficiency of treatment strategies is one of the main obstacles to developing cancer inhibitors. Up to now, various classes of therapeutics have been developed to inhibit cancer progression. Peptides due to their small size and easy production compared to proteins are highly regarded in designing cancer vaccines and oncogenic pathway inhibitors. Although peptides seem to be a suitable therapeutic option, their short lifespan, instability, and low binding affinity for their target have not been widely applicable against malignant tumors. Given the peptides’ disadvantages, a new class of agents called peptidomimetic has been introduced. With advances in physical chemistry and biochemistry, as well as increased knowledge about biomolecule structures, it is now possible to chemically modify peptides to develop efficient peptidomimetics. In recent years, numerous studies have been performed to the evaluation of the effectiveness of peptidomimetics in inhibiting metastasis, angiogenesis, and cancerous cell growth. Here, we offer a comprehensive review of designed peptidomimetics to diagnose and treat cancer.

show abstract

Section: The Ability Of Peptidomimetics On Angiogenesis Inhibitionmentioning

confidence: 99%

Peptidomimetics in cancer targeting

Gomari

Abkhiz

Pour

et al. 2022

Mol Med

View full text Add to dashboard Cite

show abstract

“…Recently, the delivery of anti-VEGF agents through topical formulations as an alternative to the more invasive intravitreal injections has been garnering attention (Dastjerdi et al, 2009;Wilkinson-Berka and Deliyanti, 2016;De Cogan et al, 2017). The success of Vasotide, a small cyclic retro-inverted peptidomimetic in an eye drop form shows the potential of such applications.…”

Section: Cds For Anti-vegf Therapymentioning

confidence: 99%

Carbon Dots Fabrication: Ocular Imaging and Therapeutic Potential

Garner

Vichare

Paulson

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Vision loss is a major complication in common ocular infections and diseases such as bacterial keratitis, age-related macular degeneration (AMD) and diabetic retinopathy (DR). The prevalence of such ophthalmic diseases represents an urgent need to develop safe, effective, and long-term treatments. Current therapies are riddled with drawbacks and limitations which calls for the exploration of alternative drug delivery mechanisms. Toxicity of the inorganic metals and metal oxides used for drug delivery raise safety concerns that are alleviated with the alternate use of, a natural and organic polymer which is both biocompatible and environmentally friendly. Carbon dots (CDs) represent a great potential in novel biomedical applications due to their tunable fluorescence, biocompatibility, and ability to be conjugated with diverse therapeutic materials. There is a growing interest on the exploitation of these properties for drug delivery with enhanced bio-imaging. However, there are limited reports of CD applications for ophthalmic indications. In this review, we focus on the CD potential and the development of translational therapies for ophthalmic diseases. The current review presents better understanding of fabrication of CDs and how it may be useful in delivering anti-bacterial agents, anti-VEGF molecules as well as imaging for ophthalmic applications.

show abstract

Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits

Giannos,

Kraft,

Luisi

et al. 2024

Pharm Res

View full text Add to dashboard Cite

Purpose Wet age-related macular degeneration (AMD) is a blinding retinal disease. Monthly intravitreal anti-VEGF antibody injections of bevacizumab (off-label) and ranibizumab (FDA approved) are the standard of care. Antibody aggregation may interfere with ocular absorption/distribution. This study assessed topical delivery of dilute antibodies to the posterior segment of rabbit eyes using a novel anti-aggregation formula (AAF). Methods Bevacizumab, or biosimilar ranibizumab was diluted to 5 mg/ml in AAF. All rabbits were dosed twice daily. Substudy 1 rabbits (bevacizumab, 100 µl eye drops): Group 1 (bevacizumab/AAF, n = 6); Group 2 (bevacizumab/PBS, n = 7) and Vehicle control (AAF, n = 1). Substudy 2 rabbits (ranibizumab biosimilar/AAF, 50 µl eye drops): (ranibizumab biosimilar/AAF, n = 8). At 14.5 days, serum was drawn from rabbits. Aqueous, vitreous and retina samples were recovered from eyes and placed into AAF aliquots. Tissue analyzed using AAF as diluent. Results Bevacizumab in AAF permeated/accumulated in rabbit aqueous, vitreous and retina 10 times more, than when diluted in PBS. AAF/0.1% hyaluronic acid eye drops, dosed twice daily, provided mean tissue concentrations (ng/g) in retina (29.50), aqueous (12.34), vitreous (3.46), and serum (0.28 ng/ml). Additionally, the highest concentration (ng/g) of ranibizumab biosimilar was present in the retina (18.0), followed by aqueous (7.82) and vitreous (1.47). Serum concentration was negligible (< 0.04 ng/ml). No irritation was observed throughout the studies. Conclusions Bevacizumab and ranibizumab, in an AAF diluent eye drop, can be delivered to the retina, by the twice daily dosing of a low concentration mAb formulation. This may prove to be an adjunct to intravitreal injections.

show abstract

The potential of anti-VEGF (Vasotide) by eye drops to treat proliferative retinopathies

Cited by 3 publications

References 19 publications

Peptidomimetics in cancer targeting

Peptidomimetics in cancer targeting

Carbon Dots Fabrication: Ocular Imaging and Therapeutic Potential

Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits

Contact Info

Product

Resources

About